Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.

McCubrey, J A

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. [electronic resource] - Leukemia Nov 2008 - 2080-90 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1476-5551

10.1038/leu.2008.207 doi


Animals
Annexin A5--metabolism
Apoptosis--drug effects
Blotting, Western
Caspases--metabolism
Cells, Cultured
Cysteine Proteinase Inhibitors--pharmacology
Doxorubicin--pharmacology
Drug Resistance
Enzyme Activation--drug effects
Enzyme Inhibitors--pharmacology
Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors
Genes, Dominant
Hematopoietic Stem Cells--drug effects
Imidazoles--pharmacology
Leupeptins--pharmacology
Mice
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Phosphorylation--drug effects
Piperazines--pharmacology
Proto-Oncogene Proteins c-mdm2--antagonists & inhibitors
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction--drug effects
Tumor Suppressor Protein p53--antagonists & inhibitors
raf Kinases--antagonists & inhibitors